More studies needed to determine risk of ILD with CDK4/6 inhibitors
Due to increases in reports of interstitial lung disease (ILD) with CDK4/6 inhibitors as a class, CDK4/6 inhibitors should be included with other drugs that may induce ILD, according to a study.
This observational, retrospective pharmacovigilance analysis used data from the FDA Adverse Event Reporting System (FAERS). There was a total of 161 reports of ILD. ILD accounted for approximately 2% and 0.3% of all reports for abemaciclib and palbocilcib/ribociclib, respectively, in the FAERS database.
An increase in reporting was noted for CDK4/6 inhibitors and abemaciclib when compared to other drugs and other anticancer agents, respectively.
There was a strong and consistent disproportionality for abemaciclib, according to sensitivity analyses. After removing reports from Japan, there were higher-than-expected instances for palbociclib and ribociclib.
Raschi E, Fusaroli M, Ardizzoni A, et al. Cyclin-dependent kinase 4/6 inhibitors and interstitial lung disease in the FDA adverse event reporting system: a pharmacovigilance assessment. Breast Cancer Res Treat. 2020;DOI: 10.1007/s10549-020-06001-w. Epub ahead of print. PMID: 33150548; PMCID: PMC7641870.